Hepatologist and Hepatology Key Opinion Leader Sven Francque joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss the current and future roles of NITs in Drug Development.
A diverse group of MASLD/MASH stakeholders joins Jörn Schattenberg and Roger Green to discuss The Liver Meeting 2024 about key breakthroughs, explore emerging research on new therapies, and reflect on collaborative efforts that advance patient care and outcomes in the field.
Global Liver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key implications for his business from what he learned at EASL Congress 2024.
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
EASL Secretary General Aleksander Krag and our other guests, Hannes Hagstrom and Michelle Long, join Jörn Schattenberg and Roger Green to discuss MASLD-related highlights of EASL Congress 2024.
SLD Think Tank 2023 co-chairs Jörn Schattenberg and Jeff Lazarus and participants Maja Thiele and Mike Betel join Louise Campbell and Roger Green to discuss high points of the recent Barcelona meting.
Sven Francque and William Alazawi join the Surfers to to consider how we have translated the lessons of previous failed trials into better designs that produce successful trials.
The launch of Rezdiffra raises this pivotal question: which MASH patients are the correct initial targets for the first MASH drug?
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
